| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Relay Therapeutics, Inc.$20.01
-0.74 (-3.57%)
D 34Pipeline Score Richly Valued Biotech · Clinical
Market Cap
2.59 B
EPS
-1.57
P/E Ratio
-
Value Trade
56.95 M
SEC Financials
Q1 2026Dilution Risk
Revenue
3.00 M
R&D Expenses
70.56 M
Operating CF
-51.11 M
Total Assets
699.61 M
Total Liabilities
57.43 M
Equity
642.18 M
D/E Ratio
12,345
7.47 %
Week
-20.55 %
1 Month
53.92 %
3 Month
112.4 %
6 Month
-56.75 %
5 Year
-61.34 %
All Time
Cash Data
Cash Position
642.07 M
Monthly Burn
17.04 M
Runway
35.7 mo
Burn Trend
StableSEC Filing
May 5, 2026
Overview
Volume
3.19 M
52 Week Range
2.83 - 17.32
% held by Insiders
24.77 %
% held by Institutions
71.21 %
Enterprise Value
1.98 B
Total Shares
178.73 M
Short %
36.88 %
Float Shares
116.71 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Relay Therapeutics, Inc.
308Total events
2Upcoming
59Tier-1 (high impact)
2020 – 2027Coverage
Upcoming catalysts 2
Event history 306
Jun 8, 2026
◆Oral PresentationPresentation
Relay Therapeutics management to participate in Goldman Sachs 47th Annual Global Healthcare Conference fireside chat
Jun 3, 2026
◆Oral PresentationPresentation
Relay Therapeutics management to participate in Jefferies Global Healthcare Conference fireside chat
May 22, 2026
◆Poster PresentationzovegalisibPresentation
Preclinical data on Zovegalisib in murine models of PIK3CA-mutant vascular malformations
PIK3CA-mutant vascular malformationssource ↗
May 20, 2026
▼Equity OfferingCorporate
Pricing of underwritten public offering of 22,916,667 shares at $12.00 per share
May 20, 2026
◆Oral PresentationzovegalisibPresentation
Initial Results of Zovegalisib in Adult and Pediatric Patients with PIK3CA-Driven Vascular Malformations
PIK3CA-driven vascular malformationssource ↗
May 19, 2026
▼Equity OfferingCorporate
Relay Therapeutics announces proposed public offering of $175 million common stock
May 19, 2026
◆Oral PresentationzovegalisibPresentation
Initial clinical data presented at ISSVA World Congress 2026
PIK3CA-driven vascular anomaliessource ↗
May 19, 2026
●Enrollment UpdatezovegalisibTrial
Pediatric dose-finding (Part 1) for ages 6-11 ongoing
PIK3CA-driven vascular anomaliessource ↗
May 5, 2026
May 5, 2026
▲Breakthrough Therapy DesignationzovegalisibDesignation
FDA granted Breakthrough Therapy designation to zovegalisib in combination with fulvestrant for PIK3CA-mutant, HR+/HER2- advanced breast cancer
PIK3CA-mutant, HR+/HER2- advanced breast cancersource ↗
May 5, 2026
▲Trial InitiationRLY-8161Trial
Initiated Phase 1/2 trial of RLY-8161 in patients with NRAS-mutant solid tumors
NRAS-mutant solid tumorssource ↗
Drug Pipeline Intelligence
D34
Pipeline Score $172M
Pipeline ValueRichly Valued
Valuation Signal3
Drugs Scored0.1x
rNPV / MCap Top 45%
Small Cap (rank 502 of 911)
Percentile RankRelay Therapeutics, Inc. faces pipeline headwinds (34/100), with $264M risk-adjusted pipeline value, led by RLY-2608 in PIK3CA Mutation (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RLY-2608 Small molecule | PIK3CA Mutation | Phase 3 | NCT05216432 | 42% | $168M | RECRUITING | 1,470 | STALLED | C (45) | Apr 30, 2027 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
zovegalisib Breakthrough | PIK3CA-driven vascular anomalies | Phase 2 | 2026-05-19 | volumetric response rate: 60%; clinical improvement: 89%; safety profile: no patients discontinuing treatment due to adverse events Read More | Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies Read More | |
zovegalisib Breakthrough | PIK3CA-driven vascular anomalies | Phase 2 | 2026-05-19 | volumetric response rate: 60%; clinical improvement: 89%; safety profile: no patients discontinuing treatment due to adverse events Read More | Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies Read More | |
zovegalisib Breakthrough | PIK3CA-driven vascular anomalies | Phase 2 | 2026-05-19 | volumetric response rate: 60%; clinical improvement: 89%; safety profile: no patients discontinuing treatment due to adverse events Read More | Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in RLAY
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
RLAY Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
RLAYRelay Therapeutics to Participate in Two Upcoming Investor Conferences in June
Relay Therapeutics will participate in two investor conferences in June 2026, including the Jefferies Global Healthcare Conference and the Goldman Sachs Global Healthcare Conference. The events will feature live webcasts available on the company's website. Relay Therapeutics is known for its innovative therapies targeting cancer and genetic diseases, with its lead asset, zovegalisib, in Phase 3 trials.
Read more →RLAYRelay Therapeutics Announces Pricing of Public Offering of Common Stock - May 20, 2026
Relay Therapeutics has announced the pricing of a public offering of 22,916,667 shares at $12.00 each, aiming to raise approximately $275 million. The offering is set to close around May 22, 2026, and includes a 30-day option for underwriters to purchase additional shares. Relay's lead asset, zovegalisib, is currently in Phase 3 trials for metastatic breast cancer.
Read more →RLAYRelay Therapeutics Announces Pricing of Public Offering of Common Stock
Relay Therapeutics has announced the pricing of a public offering of 22,916,667 shares at $12.00 each, aiming to raise around $275 million. The offering includes a 30-day option for underwriters to purchase additional shares. The transaction is expected to close on May 22, 2026, pending customary conditions.
Read more →RLAY▲ +7.9%on this newsshared move
Relay Therapeutics Announces Proposed Public Offering of Common Stock - May 19, 2026
Relay Therapeutics has announced a public offering of $175 million in common stock, with an option for underwriters to purchase an additional 15%. The offering is being managed by notable financial institutions and is subject to market conditions. Relay's lead asset, zovegalisib, is currently in a Phase 3 trial for metastatic breast cancer.
Read more →RLAYRelay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies
Relay Therapeutics has reported promising initial clinical data for zovegalisib in treating PIK3CA-driven vascular anomalies. In the Phase 2 ReInspire trial, 60% of patients achieved a volumetric response, with 89% reporting clinical improvement at 12 weeks. The safety profile indicates potential for chronic use, with no patients discontinuing treatment due to adverse events.
Read more →RLAYRelay Therapeutics Announces Proposed Public Offering of Common Stock
Relay Therapeutics has announced a proposed public offering of $175 million in common stock. The offering is underwritten and includes a 30-day option for underwriters to purchase additional shares. The company aims to use the proceeds to support its clinical-stage development of therapies for cancer and genetic diseases, including its lead asset, zovegalisib, currently in Phase 3 trials.
Read more →RLAYRelay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates FDA Breakthrough Therapy designation granted to zovegalisib for PIK3CA-mutant, HR+/HER2- advanced breast cancer, the Phase 3 ReDiscove
Relay Therapeutics reported its financial results for Q1 2026, highlighting significant progress in developing zovegalisib, which received FDA Breakthrough Therapy designation for specific advanced breast cancer. The company also presented phase 3 data showcasing promising efficacy of zovegalisib in combination therapies. In addition, Relay Therapeutics initiated a Phase 1/2 trial for another compound, RLY-8161, addressing NRAS-mutant solid tumors. The financial results showed robust cash reserves, positioning the company well for future trials and developments.
Read more →RLAYRelay Therapeutics to Announce First Quarter 2026 Financial Results and Corporate Highlights on May 5, 2026
Relay Therapeutics will announce its first quarter 2026 financial results and corporate highlights on May 5, 2026. The company focuses on developing precision medicine therapies for cancer and genetic diseases. Its lead asset, zovegalisib, is currently in a Phase 3 trial for metastatic breast cancer and is also being explored for genetic disease indications.
Read more →RLAYRelay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer
Relay Therapeutics announced promising clinical data for its triplet regimen of zovegalisib, atirmociclib, and an aromatase inhibitor in frontline metastatic breast cancer. The combination demonstrated a 44% overall response rate in heavily pre-treated patients, with plans to initiate a Phase 3 trial in early 2027. The data suggests a well-tolerated treatment option, although further regulatory feedback is required.
Read more →RLAYRelay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026
Relay Therapeutics announced that initial clinical results for zovegalisib will be presented at the ISSVA World Congress 2026. The data will include results from approximately 20 efficacy-evaluable patients. Zovegalisib is a mutant-selective PI3Kα inhibitor aimed at treating vascular anomalies and has shown potential in preclinical studies.
Read more →RLAYRelay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026 400mg BID fed is the dose used in the ongoing Phase 3 ReDiscover-2
Relay Therapeutics presented data on zovegalisib (RLY-2608) combined with fulvestrant at the ESMO Targeted Anticancer Therapies Congress 2026. The Phase 3 ReDiscover-2 trial, which uses a 400mg BID fed dosage, demonstrated a median progression-free survival of 11.1 months among heavily pre-treated patients with metastatic breast cancer. The safety profile is consistent with prior trials, showing that the treatment is generally well-tolerated with manageable adverse effects. The results support the advancement of this promising regimen in the ongoing clinical trial.
Read more →RLAYRelay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones Initial Phase 1 data of zovegalisib in PIK3CA-driven vascular anomalies expected to be announced in
Relay Therapeutics announced its fourth quarter and full-year 2025 financial results, highlighting a significant cash position of approximately $555 million. The company outlined several key milestones for 2026, including the anticipated Phase 1 data for zovegalisib, which has received Breakthrough Therapy designation from the FDA. Initial data will also be presented for zovegalisib in PIK3CA-driven vascular anomalies and in combination with fulvestrant for metastatic breast cancer. Despite a report of substantial net losses and decreased cash reserves year-over-year, the company maintains a focus on long-term growth and commercialization of its therapies.
Read more →RLAYRelay Therapeutics to Participate in Two Upcoming Investor Conferences in March 2026
Relay Therapeutics announced its participation in two investor conferences scheduled for March 2026. The events will include live webcasts accessible via the company's website. Relay is known for its innovative therapies targeting cancer and genetic diseases, with its lead asset, zovegalisib, currently in a Phase 3 trial for metastatic breast cancer.
Read more →RLAYRelay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026
Relay Therapeutics, a clinical-stage company focused on precision medicine, will announce its fourth quarter and full year financial results for 2025 on February 26, 2026. This announcement will follow the close of U.S. financial markets, providing insights into the company's performance and corporate highlights for the fiscal year. As a company developing treatments for cancer and genetic diseases, this update is significant for stakeholders and investors alike.
Read more →RLAYRelay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
Relay Therapeutics will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11, 2026. The event will feature a live webcast of a fireside chat with the company's management. Relay is known for its innovative therapies targeting cancer and genetic diseases, including its lead asset, zovegalisib, currently in Phase 3 trials.
Read more →RLAY▲ +6.4%on this newsshared move
Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer
Relay Therapeutics announced that the FDA has granted Breakthrough Therapy designation to zovegalisib in combination with fulvestrant for treating advanced breast cancer with PIK3CA mutations. This designation is based on promising clinical data from the ReDiscover trial. The company plans to present further data at the upcoming ESMO Congress.
Read more →RLAYRelay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025
Relay Therapeutics has presented interim clinical data for zovegalisib (RLY-2608) at the 2025 San Antonio Breast Cancer Symposium. The results indicate a median progression-free survival (PFS) of 10.3 months across all patients and 11.4 months in second-line patients, with a notable objective response rate. The analysis highlights the drug's effectiveness across various patient subgroups, regardless of prior treatments or mutation status. Ongoing trials will continue to assess zovegalisib's role in treating advanced breast cancer.
Read more →RLAY▼ -7.4%on this news
Relay Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates
Relay Therapeutics reported its third quarter 2025 financial results, highlighting clinical progress in RLY-2608 trials for breast cancer and vascular malformations. The company appointed Lonnel Coats and Habib Dable to its Board of Directors to enhance commercialization efforts. Despite a net loss of $74.1 million, Relay maintains a strong cash position of $596 million to support ongoing operations.
Read more →RLAYRelay Therapeutics to Participate in Two Upcoming Investor Conferences in November
Relay Therapeutics will participate in two investor conferences in November, showcasing their commitment to engaging with stakeholders. The company is known for developing precision medicine for cancer and genetic diseases, with their lead asset, RLY-2608, currently in a Phase 3 trial for metastatic breast cancer. The events will be accessible via their website, with replays available for 30 days.
Read more →RLAYRelay Therapeutics to Announce Third Quarter 2025 Financial Results and Corporate Highlights on November 6, 2025
Relay Therapeutics, a clinical-stage precision medicine company, is set to announce its financial results for the third quarter of 2025 and corporate highlights on November 6, 2025. This report will be made public after the closing of the U.S. financial markets. The company’s efforts to revolutionize drug discovery through advanced technologies will be an anticipated focus of the announcement.
Read more →RLAYRelay Therapeutics to Participate in Two Upcoming Investor Conferences in September
Relay Therapeutics, a company focused on developing therapies for cancer and genetic diseases, has announced its upcoming participation in two investor conferences in September. The events will feature fireside chats at the Wells Fargo Healthcare Conference and the Morgan Stanley Global Conference. Both sessions will be available through webcasts, aiming to engage potential investors and stakeholders. This initiative reflects Relay's efforts to enhance its outreach and market presence.
Read more →RLAYRelay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates Presented updated data at ASCO showing consistency with prior data, including 10.3-month median PFS and 39% ORR in patients with PI3K
Relay Therapeutics has announced its second quarter 2025 financial results, highlighting the initiation of the Phase 3 ReDiscover-2 trial for RLY-2608 in HR+/HER2- metastatic breast cancer. Updated results presented at the ASCO meeting showed a median progression-free survival (PFS) of 10.3 months and an objective response rate (ORR) of 39% in patients with PI3K mutations. The company has reported $657 million in cash, sufficient to support operations until 2029, despite posting a net loss of $70.4 million in Q2 2025.
Read more →RLAYRelay Therapeutics to Announce Second Quarter 2025 Financial Results and Corporate Highlights on August 7, 2025
Relay Therapeutics is set to announce its second quarter 2025 financial results and corporate highlights on August 7, 2025. The company, known for its innovative approach in drug discovery, aims to transform the industry by integrating computational and experimental technologies. Their focus is on enhancing small molecule therapies for oncology and genetic diseases.
Read more →RLAYRelay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors
Relay Therapeutics has appointed Claire Mazumdar, Ph.D., to its Board of Directors, effective June 9, 2025. Dr. Mazumdar's extensive experience in clinical-stage oncology is expected to provide valuable guidance as the company prepares to initiate its Phase 3 ReDiscover-2 trial in breast cancer. This strategic move aims to enhance the company's capabilities in drug discovery.
Read more →RLAY▲ +6%on this news
Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025
Relay Therapeutics has announced updated interim data for RLY-2608, demonstrating a median progression-free survival (PFS) of 11.0 months in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer. The data supports the initiation of a pivotal Phase 3 trial, ReDiscover-2, expected to start in mid-2025. The treatment has shown a favorable tolerability profile, with mostly low-grade adverse events.
Read more →RLAYRelay Therapeutics to Participate in Two Upcoming Investor Conferences
Relay Therapeutics, a clinical-stage precision medicine company, has announced its participation in two upcoming investor conferences: the BoA Securities 2025 Healthcare Conference on May 14 and TD Cowen’s 6th Annual Oncology Innovation Summit on May 27. The company’s management will engage in fireside chats, which will be webcast live and available for replay for up to 30 days. This involvement signals Relay's commitment to connecting with investors and promoting its innovative approach to drug discovery.
Read more →RLAYRelay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates Cash runway extended into 2029 Initiation of Phase 3 ReDiscover-2 trial on track for mid-2025 Initiated Phase 1 RLY-2608 vascular malf
Relay Therapeutics has announced its financial results for the first quarter of 2025, highlighting an extended cash runway that will fund operations into 2029. The company is on track to initiate the Phase 3 ReDiscover-2 trial for RLY-2608 in mid-2025, alongside the initiation of a Phase 1 trial for vascular malformations. Despite these advancements, Relay reported a net loss of $77.1 million and a decrease in revenue compared to the previous year, reflecting ongoing financial challenges.
Read more →RLAYRelay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025
Relay Therapeutics is scheduled to announce its financial results for the first quarter of 2025 on May 5, 2025, after U.S. market close. The company is recognized for integrating advanced computational and experimental technologies in its drug discovery processes. This announcement reflects the company's continued operational developments in the biopharma space.
Read more →RLAYRelay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates Initiation of Phase 3 ReDiscover-2 trial of RLY-2608 + fulvestrant anticipated in the middle of 2025 in PI3Kα-mut
Relay Therapeutics reported its financial results for Q4 and the full year of 2024, highlighting significant progress in its clinical development efforts. The company anticipates initiating the Phase 3 ReDiscover-2 trial for RLY-2608 + fulvestrant in mid-2025, building on promising interim data showing a median progression-free survival (PFS) of 11.4 months in certain breast cancer patients. While Relay's cash reserves stand at approximately $780 million, reflecting a solid financial position, it also reported a decrease in revenue and a substantial net loss for the year.
Read more →RLAY▲ +6.1%on this newsshared move
Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025
Relay Therapeutics, a clinical-stage precision medicine company, plans to announce its fourth quarter and full year 2024 financial results on February 26, 2025. This report will come after the U.S. financial markets close, providing insights into the company's recent corporate highlights. The use of advanced computational and experimental technologies signifies Relay's ongoing commitment to transforming the drug discovery process.
Read more →RLAY▲ +7.4%on this news
Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regar
Relay Therapeutics provided a presentation at the J.P. Morgan Conference detailing its forward-looking statements regarding the development of its drug candidates, particularly RLY-2608 for breast cancer. The company anticipates important milestones and clinical updates in 2025, aiming to address significant unmet medical needs in various conditions. However, it acknowledges several risks, including potential delays in clinical trials and regulatory challenges. The financial health of the company appears strong, with substantial cash resources available to support ongoing research and development efforts.
Read more →RLAYRelay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
Relay Therapeutics, a clinical-stage precision medicine company, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025. The presentation will be led by Sanjiv Patel, M.D., the company's President and CEO. Attendees can access the live webcast through Relay Therapeutics' website, with an archived replay available for 30 days post-event. This event highlights Relay's commitment to advancing drug discovery through innovative technologies.
Read more →RLAY▲ +12.4%on this news
Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival New interim data show 11.4-month median PFS in 2L patient
Relay Therapeutics has announced updated interim data for its investigational drug RLY-2608 in combination with fulvestrant for treating PI3K-mutated, HR+/HER2- metastatic breast cancer. The data revealed a median progression-free survival of 11.4 months for patients receiving this treatment, which is more than doubled compared to current treatment standards. The company plans to initiate a pivotal study in 2025, highlighting the continued development of RLY-2608 as a promising option in precision oncology. The results were presented at the San Antonio Breast Cancer Symposium.
Read more →RLAYRelay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium
Relay Therapeutics announced they will present updated clinical data on RLY-2608 at the 2024 San Antonio Breast Cancer Symposium. The drug is being evaluated for its efficacy in treating patients with PIK3CA-mutated, HR+, HER2- breast cancer. The presentation is set for December 11, 2024, and aims to spotlight the therapeutic potential of RLY-2608 in a significant patient population. A conference call will also take place on the same day to discuss the findings.
Read more →RLAY▼ -6%on this news
Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors
Relay Therapeutics and Elevar Therapeutics have entered into an exclusive global licensing agreement for lirafugratinib (RLY-4008), an FGFR2 inhibitor for cholangiocarcinoma and other tumors. Under the agreement, Elevar gains worldwide rights to develop and commercialize the drug while Relay stands to receive up to $500 million in milestone payments. Lirafugratinib has shown promising efficacy in previous studies and received breakthrough and orphan drug designations from the FDA. This partnership allows Relay to prioritize other programs in its pipeline while Elevar expands its oncology portfolio.
Read more →RLAYRelay Therapeutics to Participate in Upcoming Investor Conferences
Relay Therapeutics, a clinical-stage precision medicine company, has announced its participation in several upcoming investor conferences. This includes the Guggenheim Healthcare Innovation Conference, Stifel 2024 Healthcare Conference, Jefferies London Healthcare Conference, and the Citizens JMP Hematology and Oncology Summit. Management's participation highlights their commitment to engaging with investors and promoting their innovative approach to drug discovery. The events will be webcast live, indicating a focus on transparency and communication.
Read more →RLAY▲ +5%on this newsshared move
Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights Reported interim RLY-2608 data demonstrating 9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER
Relay Therapeutics reported its financial results and key updates for Q3 2024, highlighting interim data for RLY-2608, a treatment for PI3Kα-mutated metastatic breast cancer, which demonstrates a median PFS of 9.2 months in heavily pre-treated patients. The company plans to begin a pivotal trial for RLY-2608 in combination with fulvestrant in 2025, capitalizing on promising clinical results. Relay also reported a cash position of approximately $840 million, expected to fund operations into the second half of 2027. However, the company recorded a net loss of $88.1 million for the quarter, and revenue dropped to zero compared to the previous year.
Read more →RLAYRelay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024
Relay Therapeutics, a clinical-stage precision medicine company, will announce its third quarter 2024 financial results along with corporate highlights. The report is scheduled for November 6, 2024, after U.S. financial markets close. This announcement reflects the company's ongoing efforts in drug discovery and investor communication.
Read more →RLAY▲ +52.4%on this newsshared move
Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival 9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metas
Relay Therapeutics has announced interim data showing that RLY-2608 achieves a median progression-free survival of 9.2 months in heavily pre-treated patients with PI3K-mutated, HR+/HER2- metastatic breast cancer. The study indicates a promising objective response rate, particularly among patients with kinase mutations. Additionally, the treatment exhibited a favorable safety profile, with a low rate of treatment-related adverse events. This data supports plans for a pivotal study anticipated to begin in 2025.
Read more →RLAYRelay Therapeutics Announces Webcast to Report RLY-2608 Data on September 9, 2024
Relay Therapeutics, Inc. announced a conference call set for September 9, 2024, to present interim data on RLY-2608 in the ongoing ReDiscover trial. The trial focuses on patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer. RLY-2608, a novel allosteric PI3Kα inhibitor, aims to address significant limitations seen in current PI3K inhibitor therapies. The drug has possible implications for a substantial number of patients in the U.S. if proven effective.
Read more →RLAYRelay Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights Announced 3 new programs, including genetic disease programs in vascular malformations, Fabry disease, as well as precision oncolo
Relay Therapeutics recently announced its financial results for the second quarter of 2024, highlighting the initiation of three new clinical programs and a significant collaboration with Pfizer for RLY-2608. The company reported a net loss of $92.2 million but maintains a strong cash position projected to sustain operations until mid-2026. Looking ahead, Relay anticipates multiple data readouts and clinical developments, including trials for vascular malformations and Fabry disease, slated to begin in 2025.
Read more →RLAYRelay Therapeutics to Announce Second Quarter 2024 Financial Results and Corporate Highlights on August 6, 2024
Relay Therapeutics, a clinical-stage precision medicine company, is set to announce its second quarter 2024 financial results and corporate highlights on August 6, 2024. The report will be released after the close of U.S. financial markets. This announcement demonstrates the company's commitment to transparency in its operations and progress in drug discovery.
Read more →RLAYRelay Therapeutics Discloses Three New Programs at New Program & Platform Event
Relay Therapeutics has unveiled three new programs at its New Program & Platform event aimed at addressing genetic diseases and precision oncology. The two genetic disease programs focus on vascular malformations and Fabry disease, while the precision oncology initiative introduces an NRAS-specific inhibitor. Relay's cash guidance remains unchanged and is projected to fund operations into the second half of 2026. The company emphasizes its Dynamo platform's efficacy in driving innovation within its research pipeline and advancing towards new clinical trials in the near future.
Read more →RLAYRelay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608 Initial triplet combination of RLY-2608 + atirmociclib + fulvestrant to be evaluated in patients
Relay Therapeutics has partnered with Pfizer to conduct a clinical trial evaluating the combination of atirmociclib, RLY-2608, and fulvestrant in patients with PI3K-mutated HR+/HER2- metastatic breast cancer. The study aims to commence by the end of 2024, focusing on potentially enhancing treatment efficacy while reducing toxicity. The collaboration highlights Relay's innovative approach to precision medicine, especially through the unique properties of RLY-2608, which could benefit a significant patient demographic in oncology.
Read more →RLAYRelay Therapeutics to Host New Program and Platform Event on June 6, 2024
Relay Therapeutics will host a New Program and Platform event on June 6, 2024, to showcase new initiatives from its pre-clinical pipeline. This hybrid event will allow for limited in-person attendance and a virtual option for wider access. Participants can register to view the live presentation or access an archived replay for a limited time following the event.
Read more →RLAY▲ +6.3%on this news
Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights Approximately $750 million in cash, cash equivalents and investments at end of Q1 2024, expected to fund operations into second hal
Relay Therapeutics has reported its first quarter 2024 financial results, highlighting approximately $750 million in cash expected to fund operations into the second half of 2026. The company achieved a significant revenue increase to $10 million, attributed to a milestone payment from Genentech. Relay continues to advance its RLY-2608 program and anticipates sharing data later this year. However, it also noted a net loss of $81.4 million for the quarter, although this represents an improvement from the previous year.
Read more →RLAYRelay Therapeutics to Announce First Quarter 2024 Financial Results and Corporate Highlights on May 2, 2024
Relay Therapeutics, a clinical-stage precision medicine company, is set to report its first quarter 2024 financial results and corporate highlights on May 2, 2024. The announcement will be made after the U.S. financial markets close. This update is part of their ongoing efforts in transforming the drug discovery process.
Read more →RLAYRelay Therapeutics to Participate in Three Upcoming Investor Conferences
Relay Therapeutics, a clinical-stage precision medicine company, will participate in three upcoming investor conferences in March 2024. These events include the TD Cowen’s 44th Annual Health Care Conference, the Leerink Partners’ 2024 Global Biopharma Conference, and the Barclays 26th Annual Global Healthcare Conference. The management will present during fireside chats, which will also be available via live webcast, promoting transparency and investor engagement.
Read more →RLAYRelay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights Completed enrollment in initial RLY-2608 600mg + fulvestrant dose expansion cohort & initiated additional dose expan
Relay Therapeutics reported its fourth quarter and full year 2023 financial results, highlighting significant advancements in its clinical programs, particularly RLY-2608. The company has completed enrollment in the initial dose expansion cohort of RLY-2608 and initiated additional cohorts while possessing approximately $750 million in cash to support operations until mid-2026. Despite reporting a substantial net loss and having no revenue in the fourth quarter, Relay remains optimistic about its clinical developments and plans to disclose further data in 2024.
Read more →RLAY▲ +7.9%on this news
Relay Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights on February 22, 2024
Relay Therapeutics, a clinical-stage precision medicine firm, has scheduled the announcement of its fourth quarter and full year 2023 financial results and corporate highlights for February 22, 2024. This update will be released after the close of U.S. financial markets. The company is noted for its advanced use of computational and experimental technologies in the drug discovery process, which aims to transform this sector.
Read more →RLAYRelay Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Relay Therapeutics will participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on February 8, 2024. The management will conduct a fireside chat that can be accessed via a live webcast from their website. An archived version of the presentation will be available for 30 days after the event, showcasing the company's advancements in drug discovery.
Read more →RLAYRelay Therapeutics Announces $30 Million Private Placement Financing
Relay Therapeutics has announced a private placement financing that will net them $30 million from the sale of 2.5 million shares at $12 each. The funds will primarily be directed towards advancing the development of RLY-2608 for treating PI3Kα-mutated, HR+, HER2- breast cancer, as well as supporting other preclinical programs. The financing is expected to close by January 10, 2024, subject to customary closing conditions. This move underscores the company's growth potential and commitment to its pipeline.
Read more →RLAY▲ +7.7%on this news
Relay Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
Relay Therapeutics, a clinical-stage precision medicine firm, will have its CEO, Dr. Sanjiv Patel, present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024. The presentation will showcase the company's advancements in drug discovery technologies. Attendees can access the live webcast through the company's website, and an archive will be available for 30 days post-event.
Read more →RLAYRelay Therapeutics to Participate in Stifel 2023 Healthcare Conference
Relay Therapeutics, Inc. will engage in a fireside chat at the Stifel 2023 Healthcare Conference scheduled for November 14, 2023. This event will provide an opportunity for management to discuss the company's initiatives. The chat will be available via live webcast, along with an archived replay for 30 days post-event, enhancing audience access.
Read more →RLAY▲ +8.3%on this news· ran to +19% by day 3shared move
Relay Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Highlights Reported initial RLY-4008 (lirafugratinib) data demonstrating durable responses across multiple FGFR2-altered solid tumors Announce
Relay Therapeutics has reported its financial results for Q3 2023, highlighting promising data from its RLY-4008 (lirafugratinib) program in treating FGFR2-altered solid tumors. The company has generated $25.2 million in revenue, a substantial increase from the previous year, and its cash reserves are projected to last until mid-2026. However, the report also notes a net loss of $65.7 million, prompting the company to pause certain development initiatives. Relay plans to advance new therapeutic combinations in HR+/HER2- breast cancer by the end of this year.
Read more →RLAY▲ +5.3%on this news
Relay Therapeutics to Announce Third Quarter 2023 Financial Results and Corporate Highlights on November 2, 2023
Relay Therapeutics, a clinical-stage precision medicine company, will announce its third quarter 2023 financial results and corporate highlights on November 2, 2023. This announcement is set to take place after the U.S. financial markets close. Such reports typically provide insights into the company's performance and future strategies.
Read more →RLAY▼ -11%on this news
Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors 35% ORR in patients with FGFR2 fusions (excluding CCA) & 40% ORR in patients
Relay Therapeutics has announced promising initial clinical data for RLY-4008, showing significant response rates in patients with FGFR2 alterations across several tumor types. A 35% overall response rate was observed in patients with FGFR2 fusions, and 40% in those with HR+/HER2- breast cancer. The data suggests durable responses, with many patients maintaining treatment for over six months. Relay's plans include ongoing trials for RLY-4008 and the initiation of RLY-2608 triplet combinations by year-end, while a pause in RLY-2139 development indicates a strategic shift.
Read more →RLAYRelay Therapeutics to Present Clinical Data on RLY-4008 in Advanced FGFR2-Altered Solid Tumors at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Relay Therapeutics announced that they will present clinical data on RLY-4008, a selective FGFR2 inhibitor, at the upcoming AACR-NCI-EORTC conference. This data will focus on patients with advanced FGFR2-altered solid tumors, excluding cholangiocarcinoma. The company's clinical trial, ReFocus, is currently underway, evaluating the efficacy of RLY-4008, with a registrational dose already established. This marks a significant step in Relay's commitment to advancing precision medicine for cancer treatment.
Read more →RLAY▲ +7.7%on this news
Relay Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Highlights Initiated dose expansion cohort for RLY-2608 600mg BID + fulvestrant in patients with PI3Kα-mutated, HR+/HER2- metastatic br
Relay Therapeutics has reported its financial results for Q2 2023, highlighting progress in its clinical pipeline, especially with RLY-2608. The company has initiated a dose expansion cohort for RLY-2608 combined with fulvestrant, showing an impressive interim clinical benefit rate of 86% among evaluable patients. Despite a net loss increase to $98.5 million, Relay's financial position remains robust with approximately $872 million in cash reserves, anticipated to fund operations through mid-2025. Further updates and milestones are expected in 2024.
Read more →RLAY▼ -5.5%on this news
Relay Therapeutics to Announce Second Quarter 2023 Financial Results and Corporate Highlights on August 8, 2023
Relay Therapeutics, a clinical-stage precision medicine company, will announce its second quarter 2023 financial results and corporate highlights on August 8, 2023. The announcement will occur after the U.S. financial markets close. This report is anticipated to provide insights into the company’s current performance and future direction as it relies on advanced drug discovery technologies.
Read more →RLAYRelay Therapeutics Announces Full Dose Escalation Data for RLY-4008 Data from FGFRi-na ve FGFR2-fusion CCA patients represent subset of September 2022 presentation and remain consistent with previously reported results C
Relay Therapeutics has announced the completion of the first-in-human dose escalation study for its drug RLY-4008, targeting FGFR2-altered cholangiocarcinoma (CCA). The data shows promising response rates, particularly in a subset of patients who had not previously received an FGFR inhibitor. The study will be further discussed at the upcoming ASCO Annual Meeting scheduled for June 4, 2023, with additional data from ongoing expansion cohorts expected later this year. Overall, the findings support the potential efficacy and safety of RLY-4008 across different patient populations.
Read more →RLAYRelay Therapeutics Reports First Quarter 2023 Financial Results and Corporate Highlights Presented initial clinical data for RLY-2608 at American Association for Cancer Research (AACR) Annual Meeting 2023 Initiated clini
Relay Therapeutics has reported positive initial clinical results for RLY-2608, showcasing its potential to selectively inhibit mutant PI3K with manageable safety profiles. The company also initiated a clinical trial for RLY-5836 and anticipates introducing expansion cohorts for RLY-2608 later this year. Despite promising developments, the company recorded a net loss of $94.2 million for the first quarter of 2023, raising questions about financial sustainability amidst rising R&D expenses. Their cash reserves are expected to support operations through 2025, suggesting a stable short-term financial outlook.
Read more →RLAYRelay Therapeutics to Announce First Quarter 2023 Financial Results and Corporate Highlights
CAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, plans to report first quarter 2
Read more →RLAYRelay Therapeutics to Present Initial Clinical Data on RLY-2608 at AACR
CAMBRIDGE, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that initial cl
Read more →RLAYRelay Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights Advanced RLY-4008: Reported interim data with 88% overall response rate at pivotal dose and 63% across all doses in
Relay Therapeutics reported its fourth quarter and full-year financial results, highlighting significant advancements in its pipeline, particularly for RLY-4008, which showed an 88% overall response rate at the pivotal dose in cholangiocarcinoma patients. The company raised $300 million and has approximately $1 billion in reserves, expected to fund operations through 2025. Additionally, progress was noted in its breast cancer portfolio with clinical studies for RLY-2608 and the initiation of three new pre-clinical programs. However, the company continues to face net losses and increasing expenses associated with research, development, and administrative operations.
Read more →RLAY▼ -5%on this news
Relay Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
CAMBRIDGE, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, plans to report fourth quarter a
Read more →RLAYRelay Therapeutics to Participate in Guggenheim Healthcare Talks | Oncology Day
CAMBRIDGE, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in a fireside chat at the Guggenheim Healthcare Talks | Oncology Day on Thursday, February 9, 2023 at 10:10 a.m. ET. The fireside chat will be webcast live and
Read more →RLAYJPM Presentation January 2023 Disclaimer This presentation contains forward-looking statements and information about our current and future prospects and our operations and financial results, which are based on currently
Relay Therapeutics presented at the JPM conference, detailing their current operations, financial condition, and forward-looking strategies. The company highlighted a strong cash position of $1.1 billion expected to fund operations into 2025 and discussed their clinical pipeline, which includes several promising candidates for various types of cancers. Relay is committed to expanding their precision medicine capabilities and anticipates important clinical data releases throughout 2023 and beyond. The presentation underscores their dedication to both existing and undisclosed programs aimed at addressing significant unmet medical needs in oncology.
Read more →RLAYRelay Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, is scheduled to present at the 4
Read more →RLAYRelay Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights Shared 88% overall response rate (ORR) from interim data of RLY-4008 in pan-FGFR treatment (FGFRi)-na ve FGFR2-fusion cholangiocarc
Relay Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights Shared 88% overall response rate (ORR) from interim data of RLY-4008 in pan-FGFR treatment (FGFRi)-na ve FGFR2-fusion cholangiocarcinoma (CCA) patients treated at the pivotal dose at Europe
Read more →RLAYRelay Therapeutics to Announce Third Quarter 2022 Financial Results and Corporate Highlights
CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, plans to report third quarter 20
Read more →RLAYRelay Therapeutics to Participate in Fireside Chat at Bank of America Securities 2022 Precision Oncology Conference
CAMBRIDGE, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, is scheduled to participate in
Read more →RLAYRelay Therapeutics Announces Proposed Public Offering of Common Stock Cambridge, MA
Relay Therapeutics Announces Proposed Public Offering of Common Stock Cambridge, MA, September 12, 2022 Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experi
Read more →RLAYLate Breaking Data Presented at ESMO Congress 2022 Demonstrate Potential of RLY-4008 to Transform Treatment Options for Cholangiocarcinoma Patients with FGFR2-Driven Disease 88% overall response rate (15 out of 17) from
Late Breaking Data Presented at ESMO Congress 2022 Demonstrate Potential of RLY-4008 to Transform Treatment Options for Cholangiocarcinoma Patients with FGFR2-Driven Disease 88% overall response rate (15 out of 17) from interim data of pan-FGFR treatment (FGFRi)-na ve FGFR2-fus
Read more →RLAY▲ +23.7%on this newsshared move
Hollebecque (ESMO 2022) RLY-4008 LBA FINAL Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with a FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-na ve cholangiocarcinoma (CCA): ReF
Hollebecque (ESMO 2022) RLY-4008 LBA Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with a FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-na ve cholangiocarcinoma (CCA): ReFocus trial Antoine Hollebecque1, Mitesh J. Borad2, Lipika Goyal3
Read more →RLAYRelay Therapeutics to Present Clinical Data on RLY-4008 at ESMO Congress
CAMBRIDGE, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that a late brea
Read more →RLAYRelay Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights Appointment of Sekar Kathiresan, M.D., CEO of Verve Therapeutics, to board of directors Disclosed three new programs from a growin
Relay Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights Appointment of Sekar Kathiresan, M.D., CEO of Verve Therapeutics, to board of directors Disclosed three new programs from a growing breast cancer portfolio and a regulatory update on RLY-4
Read more →RLAY▼ -5.7%on this news
Relay Therapeutics to Announce Second Quarter 2022 Financial Results and Corporate Highlights
CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, plans to report second quarter 2
Read more →RLAY▼ -10.5%on this news· ran to -22% by day 1
Relay Therapeutics Discloses Anticipated Registrational Path for RLY-4008 in Cholangiocarcinoma and Growing Breast Cancer Franchise at Virtual Analyst and Investor Event End-of-phase 1 meeting with the U.S. Food and Drug
Relay Therapeutics Discloses Anticipated Registrational Path for RLY-4008 in Cholangiocarcinoma and Growing Breast Cancer Franchise at Virtual Analyst and Investor Event End-of-phase 1 meeting with the U.S. Food and Drug Administration (FDA) resulted in alignment on the design o
Read more →RLAYRelay Therapeutics Announces Timing of Virtual Analyst and Investor Event
CAMBRIDGE, Mass., June 16, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced registration is
Read more →RLAY▼ -9.1%on this news· ran to -34% by day 3
Relay Therapeutics Reports First Quarter 2022 Financial Results and Corporate Highlights Initiated the fulvestrant combination arm of the first-in-human trial for RLY-2608, a pan-mutant and isoform-selective PI3Kα
Relay Therapeutics Reports First Quarter 2022 Financial Results and Corporate Highlights Initiated the fulvestrant combination arm of the first-in-human trial for RLY-2608, a pan-mutant and isoform-selective PI3K inhibitor, and continued to enroll patients in the single agent ar
Read more →RLAYRelay Therapeutics to Participate in Fireside Chat at Bank of America Securities 2022 Healthcare Conference
CAMBRIDGE, Mass., May 03, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in a fireside chat at the Bank of America Securities 2022 Healthcare Conference on Tuesday, May 10, 2022, at 3:20 p.m. PT in Las Vegas, NV. The fireside chat wil
Read more →RLAYRelay Therapeutics to Announce First Quarter 2022 Financial Results and Corporate Highlights
CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, plans to report first quarter 2
Read more →RLAY▲ +5.9%on this news· ran to +17% by day 3
Relay Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights Announced RLY-4008 interim clinical data that suggest it is the first investigational therapy that selectively binds
Relay Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights Announced RLY-4008 interim clinical data that suggest it is the first investigational therapy that selectively binds to FGFR2 and avoids off-isoform toxicities in the treatmen
Read more →RLAYRelay Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights
CAMBRIDGE, Mass., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, plans to report fourth quarter a
Read more →RLAYDisclaimer This presentation contains forward-looking statements and information about our current and future prospects and our operations and financial results, which are based on currently available information. All st
40th Annual J.P. Morgan Healthcare Conference Company Presentation January 2022 Exhibit 99.1 Disclaimer This presentation contains forward-looking statements and information about our current and future prospects and our operations and financial results, which are based on curre
Read more →RLAYRelay Therapeutics Announces Dosing of First Patient in First-in-Human Trial of RLY-2608 and Initiation of Expansion Cohorts for First-In-Human Trial of RLY-4008
Doses first patient in first-in-human trial of RLY-2608, a pan-mutant and isoform-selective PI3Kα inhibitor Selects 70 mg once-daily dose for RLY-4008 and initiates expansion cohorts in patients with FGFR2-altered solid tumors, including cholangiocarcinoma and breast cancer CAM
Read more →RLAY▲ +5.4%on this newsshared move
Relay Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 9:45 a.m. ET. The presentation will be webcast live and may be accessed through
Read more →RLAYRelay Therapeutics Announces Preclinical Data that Support Clinical Development of RLY-2608 as Both a Single Agent and in Combination
CAMBRIDGE, Mass., Dec. 10, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today shared additional preclini
Read more →RLAYRelay Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights Cambridge, MA
Relay Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights Cambridge, MA - November 10, 2021 - Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-e
Read more →RLAYRelay Therapeutics to Announce Third Quarter 2021 Financial Results and Recent Corporate Highlights
CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, plans to report third quarter 20
Read more →RLAY▲ +8.3%on this news· ran to +26% by day 3shared move
Relay Therapeutics Announces Interim Clinical Data that Support RLY-4008 as a Highly Selective FGFR2 Inhibitor
Interim data suggest that RLY-4008 is a highly selective FGFR2 inhibitor that has not shown to be limited by off-target toxicities of hyperphosphatemia (FGFR1) and diarrhea (FGFR4) RLY-4008 demonstrated tumor shrinkage in all six pan-FGFR treatment-naïve FGFR2 fusion positive ch
Read more →RLAY▼ -11.9%on this newsshared move
Relay Therapeutics Announces Preclinical Data that Support RLY-2608 as the First Known Allosteric Pan-Mutant Selective Inhibitor of PI3K RLY-2608 preferentially binds mutant PI3K at a novel allosteric site discovered by
Relay Therapeutics Announces Preclinical Data that Support RLY-2608 as the First Known Allosteric Pan-Mutant Selective Inhibitor of PI3K RLY-2608 preferentially binds mutant PI3K at a novel allosteric site discovered by the Dynamo platform Preclinically, achieved tumor regre
Read more →RLAY▲ +11%on this news
Relay Therapeutics to Present Clinical Data on RLY-4008 and Preclinical Data on RLY-2608 at AACR-NCI-EORTC Molecular Targets Conference
CAMBRIDGE, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading edge computational and experimental technologies, today announced that initial cl
Read more →RLAYRelay Therapeutics Announces Corporate Updates and Reports Second Quarter 2021 Financial Results Company selected RLY-2608 as PI3K mutant inhibitor development candidate and plans to initiate first-in-human study in the
Relay Therapeutics Announces Corporate Updates and Reports Second Quarter 2021 Financial Results Company selected RLY-2608 as PI3K mutant inhibitor development candidate and plans to initiate first-in-human study in the first half of 2022 RLY-2608 potently inhibits mutants H104
Read more →RLAYRelay Therapeutics to Announce Second Quarter 2021 Financial Results and Recent Corporate Highlights
CAMBRIDGE, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading edge computational and experimental technologies, plans to report second quarter 2
Read more →RLAYRelay Therapeutics to Participate in Fireside Chat at the Cowen 2nd Annual Oncology Innovation Summit
CAMBRIDGE, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in a fireside chat at the Cowen 2nd Annual Virtual Oncology Innovation Summit on Thursday May 20, 2021 at 11:20am ET. The fireside chat will be webcast live and
Read more →RLAYRelay Therapeutics Reports First Quarter 2021 Financial Results Cambridge, MA
Relay Therapeutics Reports First Quarter 2021 Financial Results Cambridge, MA - May 13, 2021 - Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading edge computational and experimental te
Read more →RLAYRelay Therapeutics Strengthens Computational Leadership Team with Addition of Patrick Riley, Ph.D.
CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading edge computational and experimental technologies, today announced the appointment o
Read more →RLAYRelay Therapeutics to Participate in Fireside Chat at Bank of America 2021 Health Care Conference
CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in a fireside chat at the Bank of America 2021 Health Care Conference on Tuesday, May 11, 2021 at 8:45 a.m. ET. The fireside chat will be webcast live and may be
Read more →RLAYRelay Therapeutics Extends Leadership in Integrating Computational and Experimental Approaches to Create Precision Medicines by Acquiring ZebiAI Relay Therapeutics leadership in this new breed of biotech positions the co
Relay Therapeutics Extends Leadership in Integrating Computational and Experimental Approaches to Create Precision Medicines by Acquiring ZebiAI Relay Therapeutics leadership in this new breed of biotech positions the company as a strategic partner of choice for emerging techn
Read more →RLAYRelay Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights Advanced two programs, RLY-1971 and RLY-4008, into clinical development, and on track to initiate IND enabling stu
Relay Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights Advanced two programs, RLY-1971 and RLY-4008, into clinical development, and on track to initiate IND enabling studies with PI3K mutant selective inhibitor in 2021 Entered
Read more →RLAYRelay Therapeutics to Present Preclinical Data on RLY-4008 at AACR Annual Meeting
CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging unparalleled insights into protein motion, today announced that preclinical data for RLY
Read more →RLAYRelay Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2021 Oncology Day
CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in a fireside chat at the Guggenheim Healthcare Talks 2021 Oncology Day on Thursday, February 11, 2021 at 3:30 p.m. ET. The fireside chat will be webcast live a
Read more →RLAYRelay Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 4:30 p.m. ET. The presentation will be webcast live and may be accessed from th
Read more →RLAYRelay Therapeutics Announces a Worldwide License and Collaboration Agreement with Genentech for RLY-1971 Collaboration brings together clinical stage SHP2 and KRAS G12C inhibitors Relay Therapeutics will receive $75 mill
Relay Therapeutics Announces a Worldwide License and Collaboration Agreement with Genentech for RLY-1971 Collaboration brings together clinical stage SHP2 and KRAS G12C inhibitors Relay Therapeutics will receive $75 million upfront and is eligible to receive an additional $25
Read more →RLAYRelay Therapeutics Reports Third Quarter 2020 Financial Results Cambridge, MA
Relay Therapeutics Reports Third Quarter 2020 Financial Results Cambridge, MA November 12, 2020 Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging unparalleled insights into protein motion,
Read more →RLAYRelay Therapeutics Announces Dosing of First Patient in First-in-Human Clinical Trial of RLY-4008, a Highly Selective FGFR2 Inhibitor
CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging unparalleled insights into protein motion, today announced the first patient has been do
Read more →RLAYRelay Therapeutics Reports Second Quarter 2020 Financial Results Cambridge, MA
Relay Therapeutics Reports Second Quarter 2020 Financial Results Cambridge, MA August 27, 2020 Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging unparalleled insights into protein motion, t
Read more →RLAYRelay Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
CAMBRIDGE, Mass., July 20, 2020 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging unparalleled insights into protein motion, today announced the closing of its initial pub
Read more →RLAYRelay Therapeutics Announces Pricing of Initial Public Offering
CAMBRIDGE, Mass., July 15, 2020 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging unparalleled insights into protein motion, today announced the pricing of its initial pub
Read more →Competitive Position
How RLAY ranks across every disease it competes inCompetitive Position is a premium feature
See how RLAY ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial